Monotherapy or in combination w/ a sulfonylurea, metformin or insulin in conjunction w/ diet, exercise & wt reduction to improve glycemic control in patient with NIDDM type 2.
Dosage/Direction for Use
Monotherapy 15-30 mg once daily. Max: 45 mg once daily. Combination therapy 15-30 mg once daily w/ current sulfonylurea, metformin or insulin.
May be taken with or without food.
NYHA class III & IV.
Type 1 diabetes, diabetic ketoacidosis, CHF, macular edema, edema, increased incidence of bone fracture especially in women, symptomatic heart failure. Ovulation may occur in premenopausal anovulatory women. Monitor fluid retention-related adverse events. Evaluate serum ALT level prior to initiation of therapy & thereafter. Childn <18 yr.
Upper resp infection, headache, sinusitis, myalgia, tooth disorder, pharyngitis, hypoglycemia during combination therapy, decrease in Hb & hematocrit, wt gain, edema, anemia, ALT & CPK elevation.